Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers

The aim was to investigate the implications of androgen receptor (AR) expression levels on outcomes for estrogen receptor (ER)-positive tumors. Immunohistochemically AR levels were determined from tissue microarrays of 614 ER-positive patients who received adjuvant endocrine with or without chemothe...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2012-05, Vol.133 (1), p.311-320
Main Authors: Park, Seho, Park, Hyung Seok, Koo, Ja Seung, Yang, Woo Ick, Kim, Seung Il, Park, Byeong-Woo
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Androgens
Antineoplastic Agents, Hormonal - therapeutic use
Aromatase Inhibitors - therapeutic use
Biological and medical sciences
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - mortality
Cancer
Cancer research
Cancer therapies
Chemotherapy
Chemotherapy, Adjuvant
Disease-Free Survival
Endocrine therapy
Epidemiology
Estrogen
Estrogens
Female
Gene Expression
Gynecology. Andrology. Obstetrics
Humans
Kaplan-Meier Estimate
Maintenance Chemotherapy
Mammary gland diseases
Medical prognosis
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Multivariate Analysis
Neoplasms, Hormone-Dependent - drug therapy
Neoplasms, Hormone-Dependent - metabolism
Neoplasms, Hormone-Dependent - mortality
Oncology
Phenols
Progesterone
Proportional Hazards Models
Receptors, Androgen - genetics
Receptors, Androgen - metabolism
Receptors, Estrogen - metabolism
Tissue Array Analysis
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim was to investigate the implications of androgen receptor (AR) expression levels on outcomes for estrogen receptor (ER)-positive tumors. Immunohistochemically AR levels were determined from tissue microarrays of 614 ER-positive patients who received adjuvant endocrine with or without chemotherapy between November 1999 and August 2005. Characteristics and survival were analyzed using a Chi-square test, Kaplan–Meier methods, and Cox’s models. AR levels were categorized into 3 subgroups as follows: low, AR 
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-011-1950-z